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onstrate that reduction in Ca2+ by chelating compound BAPTA-AM or by IP3-endoplasmic reticulum
blocker 2-APB selectively inhibited VEGF-induced activation of c-Src-PI3K-Akt but not ERK1/2 in
human coronary artery endothelial cells (HCAEC). We also show that the selective inhibitory effects
of NADPH oxidase knockdown on VEGF-mediated activation of c-Src-PI3K-Akt signaling and cell
proliferation in HCAEC can be reversed by increase in intracellular Ca2+. These results suggest an
essential role for Ca2+ in redox-dependent selective activation of c-Src-PI3K-Akt and endothelial cell
proliferation.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Vascular endothelial growth factor (VEGF) is a potent endothelial
cell (EC)-speciﬁc mitogen and chemotactic factor that is involved in
wound repair, angiogenesis of ischemic tissue, tumor growth,
microvascular permeability, vascular protection, and hemostasis
[1,2]. In addition to its mitogenic and chemotactic properties, VEGF
promotes EC survival [3–5]. The VEGF family of proteins binds to
three major receptor-type tyrosine kinases, Flt-1 (VEGF receptor-
1), KDR/Flk-1 (VEGF receptor-2), and VEGFR-3 [6,7]. Upon binding
to its receptor(s), VEGF activates a number of different intracellular
signaling pathways, including phospholipase Cc, protein kinase C,
mitogen-activatedproteinkinase (MAPK)/extracellular signal-regu-
lated kinase (ERK), nonreceptor tyrosine kinase c-Src, and phospha-
tidyl inositol 3-kinase (PI3K)/Akt/protein kinase B in ECs.
Recently, we have demonstrated that selective VEGF signaling
pathway c-Src-PI3K-Akt but not ERK1/2 is dependent on NADPH
oxidase-derived reactive oxygen species (ROS) [8]. Although ROS
have traditionally been considered harmful for the endothelium,
recent ﬁndings suggest that ROS play critical roles in signal trans-
duction in ECs. Speciﬁcally, we have demonstrated that VEGF in-
duces the activity of NADPH oxidase [9,10], a multi-subunitchemical Societies. Published by E
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edical Center, RN-232, 330
ax: +1 617 667 2913.
id).enzyme complex consists of two membrane-bound components,
gp91phox (also known as Nox2) and p22phox, and several cytosolic
regulatory subunits, including p47phox, p67phox, and the small
GTPase Rac (Rac1 or Rac2). We have also shown that NADPH oxi-
dase is a major source of endothelial ROS and that NADPH oxi-
dase-derived reactive oxygen species (ROS) are, in turn, required
for VEGF-mediated induction of cell proliferation, migration and
gene expression [8–11].
Subsequent studies have conﬁrmed the importance of ROS in
VEGF signal transduction [12,13].
Calcium acts as a second messenger and plays important role in
many cellular functions including survival and proliferation. VEGF
requires Ca2+ for EC proliferation and plays a critical role in the reg-
ulation of intracellular ionized calcium (Ca2+) concentration [14].
VEGF induces inﬂux of Ca2+ from the extracellular space in re-
sponse to store depletion caused by activation of the transmem-
brane store-operated channels/capacitative Ca2+ entry channels
(SOC/CCE) in ECs [15,16]. VEGF also regulates PLCc-(PIP2)-IP3-med-
iated activation of inositol 1,4,5-trisphosphate receptor (IP3R)
resulting in the release of Ca2+ from the endoplasmic reticulum
(ER) into the cytosol [15,17]. Furthermore, inhibition of VEGFR2,
Src and IP3 was shown to eliminate calcium and membrane poten-
tial transients in HUVEC [16]. The present study is aimed to eluci-
date the role of Ca2+ in VEGF signaling in ECs and to examine the
interrelationship, if any, between ROS and Ca2+ in VEGF signal
transduction. Here, we report an interesting ﬁnding that VEGF-
mediated activation of redox-sensitive c-Src-PI3K-Akt but notlsevier B.V. All rights reserved.
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also demonstrate that an increase in intracellular Ca2+ can com-
pensate for the effects of reduction in NADPH oxidase activity on
VEGF-induced activation of c-Src-PI3K-Akt and cell proliferation
in HCAEC.
2. Materials and methods
2.1. Cell culture and reagents
Human coronary artery endothelial cells (HCAEC) were obtained
from Clonetics and grown in Endothelial Growth Medium-2-MV
(EGM-2-MV) BulletKit (Clonetics, San Diego, CA) at 37 C and 5%
CO2. Endothelial cells from passage 3 to 6 were used for all experi-
ments. Cells were serum starved in 0.5% fetal bovine serum (FBS) for
16 h prior to treatment with 50 ng/ml human VEGF-A165 (Pepro-
Tech Inc, Rocky Hill, NJ). Where indicated, cells were pre-incubated
for 15 min with cell-permeable calcium chelator BAPTA-AM
5 lmol/l, calcium ionophore A23187 1 lmol/l, store-depletion-
mediated enhancer of intracellular calcium thapsigargin 1 lmol/l,
or inhibitor of IP3-mediated release of calcium 2-Aminoethyl diphe-
nyl borate (2-APB) 5 lmol/l (Calbiochem, San Diego, CA). XTT assay
kit was from Roche Applied Science (Indianapolis, IN).
2.2. siRNA transfection
HCAEC were grown to 70–80% conﬂuence in 6-cm plates and
transfected with 100 nM ON-TARGETplus si-RNA against p47phox
(Dharmacon, Lafayette, CO) or scrambled siRNA (Scram-si) in
Opti-MEM containing 10 lg/ml Lipofectin (Invitrogen, Carlsbad,
CA) for 5 h. The cells were then incubated in EGM-2-MV medium
for 24 h and serum starved in endothelial basal medium (EBM-2;
Clonetics) containing 0.2% serum for 16 h prior to VEGF treatment.Fig. 1. VEGF-induced activation of c-Src, FAK and Akt, but not ERK1/2 requires intracellul
described in Section 2. Serum-starved HCAEC were pre-treated with 5 lmol/l BAPTA-AM
were sequentially blotted, stripped and re-probed with the antibodies shown. Anti-b-a
independent experiments. Lower two panels: bar graph shows quantitative densitometri
at 5 min time points in three independent Western blots using NIH J image (-fold change
vehicle-pretreated followed by VEGF treatment vs. BAPTA-AM-pre-treated followed by V
treated with 1 lmol/l A23187 for 15 min and probed for phosphorylation of c-Src, FAK, Ak
and FAK phosphorylation at 5 min in three independent Western blots. *P < 0.05, VEGF-2.3. Western blotting
HCAEC were harvested for total protein and Western blots were
carried out as previously described [18]. Phospho-speciﬁc antibod-
ies against Y416-c-Src, Ser-473 Akt, focal adhesion kinase (FAK),
PLCc-1, and ERK1/2 were purchased from Cell Signaling (Beverly,
MA). Anti-b-actin antibodies were from Sigma. Western blots were
performed in triplicates using cell extracts prepared from three
independent experiments.
2.4. Cell proliferation assay
XTT assay was employed to determine cell proliferation in
HCAEC as described [19]. This assay is based on the conversion of
the yellow tetrazolium salt XTT into an orange, water-soluble
dye, formazan, by metabolically active cells. Scram-si and si-
p47phox-transfected HCAEC were serum-strarved for 12 h, pre-trea-
ted with vehicle (DMSO) or calcium ionophore A23187 for 15 min
and then treated with VEGF for 20 h. HCAEC were then incubated
with XTT for 4 h. Formation of formazan was directly quantitated
in 96-well plates with an enzyme-linked immunosorbent assay
reader at A490–655 nm (model 680; Bio-Rad). Trypan blue exclu-
sion method was also used to count the number of viable cells
where indicated as described previously [10,19].
2.5. Rac1 activity assay
HCAEC pre-treated with or without A23187 for 5 min followed
by VEGF treatment for 1 min were lysed in ice-cold lysis buffer
(25 mM HEPES, 150 mM NaCl, 10 mMMgCl2, 1 mM EDTA, 1% Non-
idet P-40, 1 mM sodium orthovanadate, 1 mM NaF and 10% glyc-
erol). Anti-active rac1-GTP antibody (New East Biosciences) and
protein A/G agarose were used to pull down GTP-bound Rac1 fromar ionized calcium. (A) Protein extracts from HCAEC were subject to Western blots as
for 15 min and treated with VEGF (50 ng/ml) for the times indicated. Membranes
ctin antibody was used as loading control. Blots shown are representative of three
c analysis of Akt phosphorylation at 15 min time points and ERK1/2 phosphorylation
expressed in mean ± S.E.M.). *P < 0.05, VEGF-treated vs. untreated control; P < 0.05,
EGF treatment. (B) Same as in (A) except, in addition to BAPTA-AM, HACEC was pre-
t and ERK1/2 at indicated time points. Bar graph shows quantitative analysis of c-Src
treated vs. untreated control.
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body as per manufacturer’s protocol.
2.6. Statistical analysis
All values are presented as mean ± S.E.M. where appropriate.
Statistical signiﬁcance between two groups was determined by
use of a paired t-test, and values of P < 0.05 were considered
signiﬁcant.
3. Results
3.1. Reduction in intracellular Ca2+ inhibits VEGF-induced activation of
c-Src-PI3K-Akt but not ERK1/2 signaling pathway
Wewanted to examine the role of intracellular Ca2+ in VEGF sig-
nal transduction in ECs. Reduction in intracellular Ca2+ levels by
cell-permeable chelating agent BAPTA-AM inhibited VEGF-medi-
ated phosphorylation of Akt but not ERK1/2 in HCAEC (Fig. 1), sug-
gesting that selective activation of some but not all VEGF signaling
pathways requires intracellular Ca2+. Decrease in intracellular Ca2+
by 2-APB, an inhibitor of IP3-mediated Ca2+ release, produced sim-
ilar results (Fig. 2). Previously, we have reported that phosphoryla-
tion of c-Src by VEGF was essential for downstream activation of
PI3K-Akt [8]. Therefore, we wanted to examine whether phosphor-
ylation of c-Src by VEGF was also dependent on intracellular Ca2+.
Fig. 1B shows that BAPTA-AM blocked c-Src and FAK phosphoryla-
tion by VEGF, suggesting that intracellular Ca2+ selectively modu-Fig. 2. Increase in intracellular Ca2+ induces Akt but not ERK1/2 phosphorylation in
HCAEC, and inhibition of IP3-mediated intracellular release of Ca2+ inhibits Akt
activation but not ERK1/2. (A) Protein extracts from HCAEC pre-treated with either
calcium ionophore (A23187) or inhibitor of IP3-mediated calcium increase (2-APB)
for 15 min, and treated with VEGF for times indicated were subject to Western
blots. Membranes were immunoblotted with anti-phospho-Akt antibody, and then
stripped and re-probed for phospho-ERK1/2. b-Actin was used as loading control.
Blots shown are representative of three independent experiments. (B and C)
Quantitative analyses of Akt (B) and ERK1/2 phosphorylation (C) were carried out as
described in Fig. 1. *P < 0.05, VEGF-treated relative to untreated control; P < 0.05,
vehicle-pretreated followed by VEGF treatment vs. A23187- or 2-APB-pre-treated
followed by VEGF treatment; and #P < 0.05, vehicle-pre-treated control vs. A23187-
pre-treated control.lates VEGF activation of c-Src-PI3K-Akt but not ERK1/2 signaling
in HCAEC.
3.2. Increase in Ca2+ selectively activates PI3K-Akt signaling but not
ERK1/2
Next, we wanted to examine the effects of increase in Ca2+ on
VEGF signaling. Increase in Ca2+ by A23187 increased basal and
VEGF-induced phosphorylation of Akt but not ERK1/2 in HCAEC
(Fig. 2) suggesting that Ca2+ plays an important role in PI3K-Akt
activation. Similar results were obtained using thapsigargin-in-
duced increase in intracellular Ca2+ (Fig. 3).
3.3. Increase in Ca2+ compensates for the effects of reduction in NADPH
oxidase activity on VEGF-induced c-Src-PI3K-Akt signaling
Previously, we have shown that VEGF-mediated activation of
c-Src-PI3K-Akt, but not ERK1/2, is dependent on NADPH oxidase-
derived reactive oxygen species (ROS) [8] (also see Figs. 3 and 4).
Together with the data presented in the current study, we hypoth-
esized that Ca2+ lies downstream of NADPH oxidase-derived ROS
in VEGF-mediated activation of c-Src-PI3K-Akt in ECs. To test
this, we next asked whether increase in Ca2+ can compensate for
a lack of NADPH oxidase activity in redox-sensitive VEGF signaling
in ECs. In NADPH oxidase-knockdown HCAEC (by si-p47phox),Fig. 3. Inhibition of NADPH oxidase blocks VEGF-mediated activation of Akt but not
ERK1/2, and thapsigargin (Tg)-mediated store-depletion-induced increase in Ca2+
induces Akt but not ERK1/2 phosphorylation. (A) Protein extracts from HCAEC
transfected with scrambled siRNA (Scram-si) and pre-treated vehicle (DMSO) for
15 min, HCAEC transfected with siRNA against p47phox (si-p47phox), or pre-treated
with thapsigargin for 15 min, and then treated with VEGF for times indicated were
subject to Western blots. Membranes were immunoblotted with anti-phospho-Akt
antibody, and then stripped and re-probed for phospho-ERK1/2. b-Actin was used
as loading control. Blots shown are representative of three independent experi-
ments. (B and C) Quantitative analyses of Akt (B) and ERK1/2 phosphorylation (C)
were carried out as described in Fig. 1. *P < 0.05, VEGF-treated relative to untreated
control; P < 0.05, scram-si treated with VEGF vs. si-p47phox-transfected treated
with VEGF; and #P < 0.05, vehicle-pre-treated control vs. thapsigargin (Tg)-pre-
treated control.
Fig. 4. (A) Excess of intracellular Ca2+ can reverse the effects of NADPH oxidase inhibition on c-Src and Akt activation in HCAEC. (A) Protein extracts from HCAEC transfected
with scrambled siRNA (Scram-si) and pre-treated with vehicle (DMSO) or A23187 for 15 min were treated with VEGF for times indicated. Western blots were performed using
anti-phospho-c-Src antibody, and then the membranes were stripped and re-probed sequentially for phospho-Akt and phospho-ERK1/2. b-Actin was used as loading control.
Blots shown are representative of three independent experiments. (B) HCAEC transfected with siRNA against p47phox (si-p47phox) and pre-treated with vehicle or A23187 for
15 min and then treated with VEGF were subject to Western blot analyses as in (A). (C–E) Quantitative analyses of c-Src (C), Akt (D) and ERK1/2 phosphorylation (E) were
carried out as described in Fig. 1. *P < 0.05, VEGF-treated relative to untreated control; P < 0.05, scram-si plus vehicle treated with VEGF vs. si-p47phox-transfected treated
with VEGF (C and D), or scram-si plus vehicle treated with VEGF vs. A23187 pre-treated HCAEC treated with VEGF (D); and #P < 0.05, vehicle-pre-treated control vs. A23187-
pre-treated control.
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was inhibited (Figs. 3 and 4B). Interestingly, increase in intracellu-
lar Ca2+ by A23187 reversed the inhibitory effects of NADPH oxi-
dase inhibition on VEGF-induced phosphorylation of c-Src and
Akt (Fig. 4B–E), suggesting that VEGF-induced redox-dependent
activation of c-Src-PI3K-Akt occurs through increase in intracellu-
lar Ca2+.
3.4. Increase in Ca2+ can reverse the inhibitory effects of NADPH
oxidase inhibition on VEGF-induced cell proliferation
We and others have previously shown that inhibition of NADPH
oxidase-derived ROS blocked VEGF-induced proliferation of ECs
including HCAEC [9,12,13]. Here, we wanted to examine whether
increase in Ca2+ can compensate for the effects of reduction of
NADPH oxidase-derived ROS on VEGF-mediated cell proliferation.
Pre-treatment of HCAEC with A23187 reversed the inhibition of
VEGF-induced cell proliferation in si-p47phox-transfected HCAEC
(Fig. 5A), suggesting that increase in Ca2+ can abrogate the inhibi-tory effects of NADPH oxidase-knockdown in HCAEC. Cell counting
assay using trypan blue exclusion method produced similar results
(data not shown).
4. Discussion
This study demonstrates that intracellular Ca2+ is required for
VEGF-mediated selective activation of c-Src-PI3K-Akt but not
ERK1/2. We have previously shown that the same pathway, c-
Src-PI3K-Akt but not ERK1/2, is also dependent on NADPH oxi-
dase-derived ROS in ECs [8]. Interestingly, the data presented in
the current study demonstrate that an excess of Ca2+ can reverse
the effects of NADPH oxidase inhibition on VEGF induction of c-
Src-PI3K-Akt signaling and cell proliferation in HCAEC. Together
with the effects of Ca2+ on cell proliferation in NADPH oxidase
knockdown ECs, the results suggest that intracellular Ca2+ plays a
positive role in the redox-sensitive activation of c-Src-PI3K-Akt.
The results also suggest that Ca2+ plausibly lies downstream of
NADPH oxidease-derived ROS in VEGF-c-Src-PI3K-Akt axis.
Fig. 5. Ca2+ can reverse the inhibitory effects of NADPH oxidase inhibition on HCAEC proliferation. XTT assay was performed on control (Scram-si) and NADPH oxidase
knockdown (si-p47phox) HCAEC that were pre-treated with or without A23187 and treated with VEGF as described in Section 2. The data represents mean ± S.E.M. of fold
change using three independent experiments. *P < 0.05, VEGF treated vs. control; P < 0.05, VEGF-treated si-p47phox-transfected vs. VEGF-treated Scram-si-transfected HCAEC.
(B) Increase in Ca2+ activates Rac1. Activated GTP-Rac1 was pulled down from HCAEC lysates that were pretreated with or without 1 lmol/l A23187 for 5 min and treated
with or without VEGF (50 ng/ml) for 1 min as indicated (upper panel). Lower panel shows Western blot using corresponding total cell lysates and anti-Rac1 antibody. (C)
Proposed model for selective requirement for intracellular Ca2+ in NADPH oxidase-dependent activation of c-Src-PI3K-Akt by VEGF in ECs. VEGF-induced activation of PLCc-1-
ERK1/2 appears to be insensitive to endothelial Ca2+ levels. The colored box indicates Ca2+-dependent VEGF signaling pathways. The ‘‘?” mark indicates as yet unknown Ca2+-
sensitive signaling intermediate(s) that modulates VEGF induction of redox-sensitive c-Src-PI3K-Akt signaling pathway.
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grate intracellular Ca2+ into the redox-sensitive component of the
VEGF signaling pathway. However, the precise mechanism of Ca2+
integration into the VEGF-redox pathway is not known at present.
A recent study reported that VEGF-induced activation of calcium/
calmodulin-dependent protein kinase kinase b (CaMKKb) resulted
in the activation of AMP-activated protein kinase (AMPK)-Rac1-
Akt pathway in BAEC [20]. Thus, it is formally possible that Rac1-
dependent NADPH oxidase-derived ROS production may depend
on Ca2+ in ECs (pre-NADPH oxidase role of Ca2+). Our ﬁndings that
increase in Ca2+ results in Rac1 activation inHCAEC (Fig. 5B) support
this notion. Alternatively, VEGF activation of c-Src-PI3K-Akt may
depend on Ca2+-sensitive upstream protein kinase(s) yet to be
indentiﬁed (post-NADPH oxidase role). Since the present study
demonstrates that an increase in Ca2+ reversed the effects of NADPH
oxidase knockdown on VEGF signaling and cell proliferation, a ma-
jor post-NADPH oxidase role for Ca2+ would be more appropriate.
These questions are currently being addressed in our laboratory.
It is evident from the above discussion that a link exists be-
tween VEGF signaling and NADPH oxidase activation in ECs as part
of an integral circuit that incorporates additional signaling input
from intracellular Ca2+ (summarized in Fig. 5C). However, the per-
missive role of Ca2+ on c-Src-PI3K-Akt signaling is very likely med-
iated at post-VEGF receptor levels. The ﬁndings that activation of
VEGFR2 is independent of Ca2+ (data not shown) and redox [8]
support this notion. In addition, redox- [8] and Ca2+-independent
activation of PLCc-1 by VEGF (data not shown) also supports a
post-VEGF receptor role for Ca2+ in c-Src-PI3K-Akt activation. It is
interesting to note that although Ca2+ inhibition did not negatively
affect VEGF-induced activation of ERK1/2, we observed a shift in
the temporal pattern and intensity of ERK1/2 activation (earliest
time point for ERK1/2 activation shifted from 1 min to 5 min) in
BAPTA-AM treated ECs (Fig. 1A). The precise mechanism for this
is not known at present. However, it is plausible that, due to inac-
tivation of PI3K-Akt, PLCc-1-ERK1/2 signaling intermediates mayhave greater access to PIP2, a common but limited substrate for
both PI3K and PLCc-1 in ECs [21]. Further studies are required to
elucidate the mechanism.
In summary, we demonstrate that VEGF-mediated activation of
redox-sensitive c-Src-PI3K-Akt but not redox-insensitive ERK1/2
signaling pathway is dependent on intracellular Ca2+, and that in-
crease in Ca2+ can compensate for the effects of loss of NADPH oxi-
dase activity on the redox-sensitive arm of VEGF signaling and cell
proliferation in HCAEC. This is the ﬁrst report to demonstrate that
Ca2+ is an integral part of the redox-dependent selective VEGF sig-
naling pathways, c-Src-PI3K-Akt but not ERK1/2, in ECs. The ﬁnd-
ings that two intracellular second messengers, Ca2+ and ROS, lie
in the same signaling axis in ECs may have important therapeutic
signiﬁcance in vascular disease state. It is worthwhile to note that
changes in endothelial Ca2+ may affect the balance of other intra-
cellular ions including phosphate, which may in turn modulate re-
dox-sensitive signaling cascade in HCAEC. Future studies to
elucidate the molecular mechanisms by which Ca2+ and ROS coor-
dinate signal propagation in the endothelium should provide
important new insights into the endothelial functions in health
and disease.
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